Drugs / DEN vaccine F17
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01843621 | Feb 2005 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEN vaccine F17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01843621 ↗ |
| Modality | Vaccine | “The tetravalent, live attenuated DEN F17 vaccine was administered in this study.” NCT01843621 ↗ |
| Route | Subcutaneous | “administered subcutaneously in the non-dominant arm (deltoid).” NCT01843621 ↗ |